Overview

This trial is active, not recruiting.

Conditions adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, recurrent adult acute myeloid leukemia
Treatments cytarabine, chk1 inhibitor sch 900776, laboratory biomarker analysis
Phase phase 2
Sponsor National Cancer Institute (NCI)
Start date May 2013
End date January 2015
Trial size 10 participants
Trial identifier NCT01870596, 9362, J1319, NCI-2013-01097, P30CA006973, U01CA070095

Summary

This randomized phase II trial studies how well cytarabine with or without SCH 900776 works in treating adult patients with relapsed acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. SCH 900776 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cytarabine is more effective with or without SCH 900776 in treating acute myeloid leukemia.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
cytarabine CHX-3311
Given IV
chk1 inhibitor sch 900776 SCH 900776
Given IV
laboratory biomarker analysis
Correlative studies
(Active Comparator)
Patients receive cytarabine as in Arm A.
cytarabine CHX-3311
Given IV
laboratory biomarker analysis
Correlative studies

Primary Outcomes

Measure
Complete response (CR/CRi) rate
time frame: Up to 3 years

Secondary Outcomes

Measure
Overall toxicity rate
time frame: Up to 3 years
Rate of each specific toxicity
time frame: Up to 3 years
AML blast cell DNA repair protein expression profiles
time frame: Up to day 4
DNA damage induced in AML blasts
time frame: Up to day 4

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Adults with the established, pathologically confirmed diagnosis of relapsed AML - AML that has relapsed at least once or is primary induction failure - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Patients must be able to give informed consent - Female patients of childbearing age must have negative pregnancy test - Serum creatinine =< 2.0 mg/dl - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit normal (ULN), unless due to Gilbert's, hemolysis or leukemic infiltration - Alkaline phosphatase =< 5 x ULN, unless due to Gilbert's, hemolysis or leukemic infiltration - Bilirubin =< 2.0 mg/dl, unless due to Gilbert's, hemolysis or leukemic infiltration - Left ventricular ejection fraction >= 45% by multi gated acquisition scan (MUGA) or echocardiogram - Baseline Fridericia corrected QT (QTcF) < 480 msec - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >= 4 weeks from stem cell infusion, have no active graft-vs-host disease (GVHD), and meet other eligibility criteria - Patients who fail primary induction therapy or relapse after achieving complete remission (CR) are eligible if they have undergone no more than 2 prior cytotoxic regimens (a regimen is described as a distinctive planned collection of agent[s] and/or modalities to be utilized together during a cycle or course of therapy; i.e., induction+consolidation with or without stem cell transplant [SCT]), >= 2 weeks off cytotoxic chemotherapy, and >= 2 weeks off radiation therapy; patients must be off biologic therapies including hematopoietic growth factors >= 2 weeks; if using hydroxyurea (HU), steroids, imatinib or other tyrosine kinase inhibitors (TKIs), interferon, or other non-cytotoxics for blast count control, patient must be off for >= 24 hours (hrs) before starting MK-8776 - Fluvoxamine and ciprofloxacin must be stopped 7 days prior to day 1 of therapy, and be excluded during administration of study therapy; if the subject is using any of the other drugs that are cytochrome P4501A2 (CYP1A2) or P-glycoprotein (PgP) inhibitors, substitution should be considered and administration of these drugs should be avoided on the days of administration of MK-8776; in addition, smoking should be avoided and cytochrome P450 3A4 (CYP3A4) substrates with a narrow therapeutic index should be avoided: alfentanil, astemizole, cisapride, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine Exclusion Criteria: - Any previous treatment with MK-8776 - Considered refractory or treatment failure to most recent treatment regimen, unless primary refractory - Concomitant chemotherapy, radiation therapy, or immunotherapy - Hyperleukocytosis with >= 50,000 blasts/uL (if using HU, steroids, tyrosine kinase/src inhibitors (including fms-related tyrosine kinase 3 [FLT3] inhibitors), arsenic, interferon or leukapheresis for blast count control, patient must be off those agents for 24 hours prior to beginning ara-C +/- MK-8776) - Acute progranulocytic leukemia (APL, M3) - Active disseminated intravascular coagulation (DIC) - Active central nervous system (CNS) leukemia - Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible - Presence of other life-threatening illness - Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol - Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-8776 - History of Fridericia corrected QT (QTcF) prolongation greater than grade 1 or 480 msec - Subjects with the following cardiac risk factors must be excluded: transmural myocardial infarction (MI) within prior 6 months, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack (TIA) or seizure disorder within 6 months prior to study drug administration - Subjects with history of risk factors for torsades de pointes: clinical history of heart failure (New York Heart Association [NYHA] class III or IV), hypo- or hyper-kalemia or hypomagnesemia (supplementation to bring levels within normal limits prior to administration of MK-8776 is acceptable) or family history of Long QT Syndrome - Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy or who have a prior history of acquired immunodeficiency syndrome (AIDS) indicator conditions, other than history of lymphoma more than 3 years remote

Additional Information

Official title Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML
Principal investigator B. Smith
Description PRIMARY OBJECTIVES: I. To compare the rates of complete remission (CR) plus CR with incomplete recovery (CRi) achieved with cytosine arabinoside (ara-C) (cytarabine) plus the checkpoint kinase 1 (CHK1) inhibitor MK-8776 (Chk1 inhibitor SCH 900776) vs. ara-C alone for adults (ages 18-75) with relapsed acute myelogenous leukemia (AML). SECONDARY OBJECTIVES: I. To evaluate and compare the toxicities of ara-C + MK-8776 vs. ara-C alone. II. To determine the disease free and overall survival of those achieving response to treatment. III. To determine the impact of MK-8776 on AML blast cell deoxyribonucleic acid (DNA) repair protein expression profiles and correlate the expression profiles with CR/CRi in response to ara-C + MK-8776 vs. ara-C alone. IV. To evaluate and compare the amount of DNA damage induced in AML blasts by ara-C + MK-8776 vs. ara-C. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive cytarabine intravenously (IV) continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12. ARM B: Patients receive cytarabine as in Arm A. In both arms, courses may repeat every 28 days. After completion of study treatment, patients are followed up periodically.
Trial information was received from ClinicalTrials.gov and was last updated in January 2015.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).